IRADIMED CORP (NASDAQ:IRMD): Institutional Investors Are Worried

IRadimed Corporation (NASDAQ:IRMD) Logo


IRADIMED CORP (NASDAQ:IRMD) institutional sentiment decreased to 1.16 in 2019 Q2. Its down -0.41, from 1.57 in 2019Q1. The ratio has dropped, as 29 investment managers increased or opened new stock positions, while 25 sold and trimmed holdings in IRADIMED CORP. The investment managers in our partner’s database reported: 3.39 million shares, up from 2.51 million shares in 2019Q1. Also, the number of investment managers holding IRADIMED CORP in their top 10 stock positions increased from 0 to 1 for an increase of 1. Sold All: 9 Reduced: 16 Increased: 21 New Position: 8.

Iradimed Corporation develops, manufactures, markets, and distributes magnetic resonance imaging compatible products, and related accessories and services in the United States and internationally. The company has market cap of $246.49 million. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets under the MRidium name; and MRI compatible patient vital signs monitoring system under the IRadimed name. It has a 32.95 P/E ratio. The firm also offers IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories; iMagox MRI pulse oximeter; and iMagox MRI oximeter remote and display products.

The stock increased 1.31% or $0.28 during the last trading session, reaching $21.68. About 58,752 shares traded. IRadimed Corporation (NASDAQ:IRMD) has risen 4.28% since October 12, 2018 and is uptrending. It has outperformed by 4.28% the S&P500.

Analysts await IRadimed Corporation (NASDAQ:IRMD) to report earnings on October, 29. They expect $0.13 EPS, up 18.18 % or $0.02 from last year’s $0.11 per share. IRMD’s profit will be $1.48 million for 41.69 P/E if the $0.13 EPS becomes a reality. After $0.17 actual EPS reported by IRadimed Corporation for the previous quarter, Wall Street now forecasts -23.53 % negative EPS growth.

Atria Investments Llc holds 2.38% of its portfolio in IRadimed Corporation for 771,677 shares. Rk Capital Management Llc owns 193,574 shares or 1.22% of their US portfolio. Moreover, Navellier & Associates Inc has 0.42% invested in the company for 131,727 shares. The Texas-based Ranger Investment Management L.P. has invested 0.38% in the stock. Cadence Capital Management Llc, a Massachusetts-based fund reported 125,751 shares.

More notable recent IRadimed Corporation (NASDAQ:IRMD) news were published by: which released: “10 High-Growth Stocks for the Return of the Bull –” on January 18, 2019, also with their article: “IRadimed Corporation Announces Pricing of Initial Public Offering – Business Wire” published on July 16, 2014, published: “IRADIMED CORPORATION Announces FDA 510(k) Clearance for Neonatal Pulse Oximetry and Capnography Monitoring Using its MRI-Compatible Patient Vital Signs Monitor – GlobeNewswire” on April 02, 2019. More interesting news about IRadimed Corporation (NASDAQ:IRMD) were released by: and their article: “IRADIMED CORPORATION to Hold 2018 Fourth Quarter Financial Results Conference Call on February 6th – GlobeNewswire” published on January 22, 2019 as well as‘s news article titled: “iRadimed: A Niche Medical Device Company With 55%+ Upside Potential – Seeking Alpha” with publication date: August 17, 2016.

IRadimed Corporation (NASDAQ:IRMD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.